enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Allergan, Inc. - Wikipedia

    en.wikipedia.org/wiki/Allergan,_Inc.

    Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]

  3. Allergan - Wikipedia

    en.wikipedia.org/wiki/Allergan

    Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.

  4. Actavis - Wikipedia

    en.wikipedia.org/wiki/Actavis

    Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...

  5. Brent Saunders - Wikipedia

    en.wikipedia.org/wiki/Brent_Saunders

    Brent Saunders (1970) is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb.He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie.

  6. Forest Laboratories - Wikipedia

    en.wikipedia.org/wiki/Forest_Laboratories

    The company was founded by Hans Lowey in 1956 as a small laboratory service company. [2]In 1967, the company became a public company via an initial public offering. [3]Ten years later, Howard Solomon became the chief executive officer of the company.

  7. Warner Chilcott - Wikipedia

    en.wikipedia.org/wiki/Warner_Chilcott

    In August 2004, the company prevailed in a patent case by Teva Pharmaceutical Industries related to Sarafem (). [5] On May 19, 2006, the company received approval from the Food and Drug Administration for Sarafem.

  8. David E. I. Pyott - Wikipedia

    en.wikipedia.org/wiki/David_E._I._Pyott

    He believed selling to Valeant would not create long-term value for Allergan's shareholders due to Valeant's historic reliance on cost-cutting. [28] Pyott is known to value aggressive research and development for Allergan, which he said had enabled Allergan to launch several new products and increase annual sales by an average of 11% since 2011 ...

  9. List of largest pharmaceutical mergers and acquisitions

    en.wikipedia.org/wiki/List_of_largest...

    Allergan, Inc: 53.3 69 Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64